News

“Today’s submission represents a significant step forward for Evofem and for the millions of women who are dissatisfied with their current contraceptive options and are eagerly awaiting a

The NDA has been accepted for the priority review of selective fibroblast growth factor receptor (FGFR) inhibitor pemigatinib to treat patients with previously treated, locally advanced or metastatic

Under the terms of the collaboration, Lonza will provide DiNAQOR preclinical, clinical and commercial production support for the company’s lead preclinical program DiNA-001, an adeno-associated virus (AAV) gene therapy program

Oxbryta, an oral therapy taken once daily, is the first approved treatment that directly inhibits sickle hemoglobin polymerization, the root cause of SCD.2,3 The medicine is expected to

The Japanese conglomerate plans to acquire Veloxis Pharmaceuticals through its Danish subsidiary Asahi Kasei Pharma Denmark in a move to accelerate its transformation into a global healthcare company.

In this connection, Ferring Pharmaceuticals has launched a new company FerGene, which will focus on the global development and US commercialisation of nadofaragene firadenovec. The gene therapy is

Health officials have identified MDR gonorrhea, a sexually transmitted bacteria, as an urgent global public health threat, exacerbated by limited diagnostics and treatment options. Each year, according to

The late-breaking data were presented by Nicholas Butowski, M.D., a principal investigator on the trial and Professor of Neurological Surgery at the University of California San Francisco Weill

Remsima SC is claimed to be the world’s first subcutaneous formulation of infliximab. The EC approval was based on clinical evidence, including results from a study that demonstrated